
Nevola50 mg
Ziska Pharmaceuticals Ltd.
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant used mainly to treat depression in adults.
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant used mainly to treat depression in adults.
A physician should determine the most appropriate indication and dose for an individual patient; Desvenlafaxine should not be used for unapproved purposes without medical advice.
Dosing of Desvenlafaxine should be individualized by a physician. General adult dosing is summarized below.
| Indication / Situation | Recommended Dosing |
|---|---|
| Major Depressive Disorder (adults) | 50 mg once daily, with or without food. Doses above 50 mg/day have not shown added benefit and are associated with more side effects; some patients may be titrated up to 100 mg/day if clinically indicated by the treating physician. |
| Renal impairment | CrCl 30-50 mL/min: maximum 50 mg/day. CrCl <30 mL/min or end-stage renal disease: 25 mg every other day (or 50 mg every other day per physician judgment); no supplemental dose after hemodialysis. |
| Hepatic impairment | Mild-to-moderate: no routine adjustment needed. Severe hepatic impairment: maximum 50 mg/day, with caution. |
| Pediatric use | Not approved; safety and efficacy not established (see Pediatric Uses). |
Discontinuation of Desvenlafaxine should always be gradual (tapered) under medical supervision rather than abrupt, to reduce the risk of discontinuation symptoms.
Side effects of Desvenlafaxine range from common and mild to rare but serious.
Desvenlafaxine is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.